Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.

Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.

Baell JB, Leaver DJ, Hermans SJ, Kelly GL, Brennan MS, Downer NL, Nguyen N, Wichmann J, McRae HM, Yang Y, Cleary B, Lagiakos HR, Mieruszynski S, Pacini G, Vanyai HK, Bergamasco MI, May RE, Davey BK, Morgan KJ, Sealey AJ, Wang B, Zamudio N, Wilcox S, Garnham AL, Sheikh BN, Aubrey BJ, Doggett K, Chung MC, de Silva M, Bentley J, Pilling P, Hattarki M, Dolezal O, Dennis ML, Falk H, Ren B, Charman SA, White KL, Rautela J, Newbold A, Hawkins ED, Johnstone RW, Huntington ND, Peat TS, Heath JK, Strasser A, Parker MW, Smyth GK, Street IP, Monahan BJ, Voss AK, Thomas T.

Nature. 2018 Aug;560(7717):253-257. doi: 10.1038/s41586-018-0387-5. Epub 2018 Aug 1.

PMID:
30069049
2.

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.

Kim SK, Knight DA, Jones LR, Vervoort S, Ng AP, Seymour JF, Bradner JE, Waibel M, Kats L, Johnstone RW.

Genes Dev. 2018 Jun 1;32(11-12):849-864. doi: 10.1101/gad.307504.117. Epub 2018 Jun 15.

3.

Tumor immune evasion arises through loss of TNF sensitivity.

Kearney CJ, Vervoort SJ, Hogg SJ, Ramsbottom KM, Freeman AJ, Lalaoui N, Pijpers L, Michie J, Brown KK, Knight DA, Sutton V, Beavis PA, Voskoboinik I, Darcy PK, Silke J, Trapani JA, Johnstone RW, Oliaro J.

Sci Immunol. 2018 May 18;3(23). pii: eaar3451. doi: 10.1126/sciimmunol.aar3451.

PMID:
29776993
4.

Down-regulation of a pro-apoptotic pathway regulated by PCAF/ADA3 in early stage gastric cancer.

Brasacchio D, Busuttil RA, Noori T, Johnstone RW, Boussioutas A, Trapani JA.

Cell Death Dis. 2018 May 1;9(5):442. doi: 10.1038/s41419-018-0470-8.

5.

A Comprehensive Protocol Resource for Performing Pooled shRNA and CRISPR Screens.

Cluse LA, Nikolic I, Knight D, Madhamshettiwar PB, Luu J, Cowley KJ, Semple T, Arnau GM, Shortt J, Johnstone RW, Simpson KJ.

Methods Mol Biol. 2018;1725:201-227. doi: 10.1007/978-1-4939-7568-6_17.

PMID:
29322420
6.

Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia.

Waibel M, Vervoort SJ, Kong IY, Heinzel S, Ramsbottom KM, Martin BP, Hawkins ED, Johnstone RW.

Leukemia. 2018 Jan;32(1):237-241. doi: 10.1038/leu.2017.282. Epub 2017 Sep 15. No abstract available.

PMID:
28914259
7.

DOCK8 Drives Src-Dependent NK Cell Effector Function.

Kearney CJ, Vervoort SJ, Ramsbottom KM, Freeman AJ, Michie J, Peake J, Casanova JL, Picard C, Tangye SG, Ma CS, Johnstone RW, Randall KL, Oliaro J.

J Immunol. 2017 Aug 9. pii: ji1700751. doi: 10.4049/jimmunol.1700751. [Epub ahead of print]

PMID:
28794229
8.

A chemical probe toolbox for dissecting the cancer epigenome.

Shortt J, Ott CJ, Johnstone RW, Bradner JE.

Nat Rev Cancer. 2017 Mar 23;17(4):268. doi: 10.1038/nrc.2017.26. No abstract available.

PMID:
28332503
9.

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.

Hein N, Cameron DP, Hannan KM, Nguyen NN, Fong CY, Sornkom J, Wall M, Pavy M, Cullinane C, Diesch J, Devlin JR, George AJ, Sanij E, Quin J, Poortinga G, Verbrugge I, Baker A, Drygin D, Harrison SJ, Rozario JD, Powell JA, Pitson SM, Zuber J, Johnstone RW, Dawson MA, Guthridge MA, Wei A, McArthur GA, Pearson RB, Hannan RD.

Blood. 2017 May 25;129(21):2882-2895. doi: 10.1182/blood-2016-05-718171. Epub 2017 Mar 10.

10.

A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.

Kats LM, Vervoort SJ, Cole R, Rogers AJ, Gregory GP, Vidacs E, Li J, Nagaraja R, Yen KE, Johnstone RW.

Leukemia. 2017 Jun;31(6):1466-1470. doi: 10.1038/leu.2017.84. Epub 2017 Mar 10. No abstract available.

PMID:
28280273
11.

Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene.

Lefebure M, Tothill RW, Kruse E, Hawkins ED, Shortt J, Matthews GM, Gregory GP, Martin BP, Kelly MJ, Todorovski I, Doyle MA, Lupat R, Li J, Schroeder J, Wall M, Craig S, Poortinga G, Cameron D, Bywater M, Kats L, Gearhart MD, Bardwell VJ, Dickins RA, Hannan RD, Papenfuss AT, Johnstone RW.

Nat Commun. 2017 Mar 6;8:14581. doi: 10.1038/ncomms14581.

12.

HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors.

Medon M, Vidacs E, Vervoort SJ, Li J, Jenkins MR, Ramsbottom KM, Trapani JA, Smyth MJ, Darcy PK, Atadja PW, Henderson MA, Johnstone RW, Haynes NM.

Cancer Res. 2017 May 15;77(10):2594-2606. doi: 10.1158/0008-5472.CAN-16-2247. Epub 2017 Mar 1.

13.

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.

Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, Beavis PA, Darcy PK, Martin BP, Spencer A, Traunbauer AK, Sadovnik I, Bauer K, Valent P, Bradner JE, Zuber J, Shortt J, Johnstone RW.

Cell Rep. 2017 Feb 28;18(9):2162-2174. doi: 10.1016/j.celrep.2017.02.011.

14.

A chemical probe toolbox for dissecting the cancer epigenome.

Shortt J, Ott CJ, Johnstone RW, Bradner JE.

Nat Rev Cancer. 2017 Feb 23;17(3):160-183. doi: 10.1038/nrc.2016.148. Review. Erratum in: Nat Rev Cancer. 2017 Mar 23;17 (4):268.

PMID:
28228643
15.

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.

Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, Davenport AJ, John LB, Mardiana S, Slaney CY, Johnstone RW, Trapani JA, Stagg J, Loi S, Kats L, Gyorki D, Kershaw MH, Darcy PK.

J Clin Invest. 2017 Mar 1;127(3):929-941. doi: 10.1172/JCI89455. Epub 2017 Feb 6.

16.

HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia.

Mehdipour P, Santoro F, Botrugno OA, Romanenghi M, Pagliuca C, Matthews GM, Johnstone RW, Minucci S.

Leukemia. 2017 Apr;31(4):995-997. doi: 10.1038/leu.2017.3. Epub 2017 Jan 24. No abstract available.

PMID:
28074065
17.

Epigenetic control of mitochondrial cell death through PACS1-mediated regulation of BAX/BAK oligomerization.

Brasacchio D, Alsop AE, Noori T, Lufti M, Iyer S, Simpson KJ, Bird PI, Kluck RM, Johnstone RW, Trapani JA.

Cell Death Differ. 2017 Jun;24(6):961-970. doi: 10.1038/cdd.2016.119. Epub 2017 Jan 6.

18.

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.

Slaney CY, von Scheidt B, Davenport AJ, Beavis PA, Westwood JA, Mardiana S, Tscharke DC, Ellis S, Prince HM, Trapani JA, Johnstone RW, Smyth MJ, Teng MW, Ali A, Yu Z, Rosenberg SA, Restifo NP, Neeson P, Darcy PK, Kershaw MH.

Clin Cancer Res. 2017 May 15;23(10):2478-2490. doi: 10.1158/1078-0432.CCR-16-1860. Epub 2016 Dec 13.

19.

In the Midst of Life-Cell Death: What Is It, What Is It Good for, and How to Study It.

Silke J, Johnstone RW.

Cold Spring Harb Protoc. 2016 Dec 1;2016(12). doi: 10.1101/pdb.top070508.

PMID:
27934692
20.

T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments.

Hawkins ED, Duarte D, Akinduro O, Khorshed RA, Passaro D, Nowicka M, Straszkowski L, Scott MK, Rothery S, Ruivo N, Foster K, Waibel M, Johnstone RW, Harrison SJ, Westerman DA, Quach H, Gribben J, Robinson MD, Purton LE, Bonnet D, Lo Celso C.

Nature. 2016 Oct 27;538(7626):518-522. doi: 10.1038/nature19801. Epub 2016 Oct 17.

21.

Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.

Lalaoui N, Hänggi K, Brumatti G, Chau D, Nguyen NN, Vasilikos L, Spilgies LM, Heckmann DA, Ma C, Ghisi M, Salmon JM, Matthews GM, de Valle E, Moujalled DM, Menon MB, Spall SK, Glaser SP, Richmond J, Lock RB, Condon SM, Gugasyan R, Gaestel M, Guthridge M, Johnstone RW, Munoz L, Wei A, Ekert PG, Vaux DL, Wong WW, Silke J.

Cancer Cell. 2016 Sep 12;30(3):499-500. doi: 10.1016/j.ccell.2016.08.009. Epub 2016 Sep 12. No abstract available.

22.

A community-based model of rapid autopsy in end-stage cancer patients.

Alsop K, Thorne H, Sandhu S, Hamilton A, Mintoff C, Christie E, Spruyt O, Williams S, McNally O, Mileshkin L, Ananda S, Hallo J, Loi S, Scott C, Savas P, Devereux L, O'Brien P, Gunawardena S, Hampson C, Strachan K, Jaravaza RD, Francis V, Young G, Ranson D, Samaranayake R, Stevens D, Boyle S, Fedele C, Topp M, Ho G, Teo ZL, Taylor RA, Papargiris MM, Lawrence MG, Wang H, Risbridger GP, Haynes NM, Medon M, Johnstone RW, Vidacs E, Arnau GM, Vergara IA, Papenfuss AT, McArthur G, Waring P, Carvosso S, Angel C, Gyorki D, Solomon B, Mitchell G, Shanley S, Francis PA, Dawson SJ, Haffenden A, Tidball E, Volchek M, Pyman J, Madadin M, Leditschke J, Cordner S; Melbourne Melanoma Project; Australian Ovarian Cancer Study Group (AOCS); Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Shackleton M, Bowtell DD.

Nat Biotechnol. 2016 Oct;34(10):1010-1014. doi: 10.1038/nbt.3674. Epub 2016 Sep 12. No abstract available.

PMID:
27617737
23.

Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement.

Chan KL, van der Weyden C, Khoo C, Lade S, Blombery P, Westerman D, Khot A, Melo B, Johnstone RW, Prince HM, Dickinson M.

Leuk Lymphoma. 2017 Apr;58(4):996-998. doi: 10.1080/10428194.2016.1222375. Epub 2016 Aug 25. No abstract available.

PMID:
27558082
24.

Constitutive IFNα/β signaling maintains expression of signaling intermediaries for efficient cytokine responses.

Messina NL, Clarke CJ, Johnstone RW.

JAKSTAT. 2016 May 18;5(1):e1173804. doi: 10.1080/21623996.2016.1173804. eCollection 2016.

25.

BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.

Hogg SJ, Newbold A, Vervoort SJ, Cluse LA, Martin BP, Gregory GP, Lefebure M, Vidacs E, Tothill RW, Bradner JE, Shortt J, Johnstone RW.

Mol Cancer Ther. 2016 Sep;15(9):2030-41. doi: 10.1158/1535-7163.MCT-15-0924. Epub 2016 Jul 12.

26.

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.

Quin J, Chan KT, Devlin JR, Cameron DP, Diesch J, Cullinane C, Ahern J, Khot A, Hein N, George AJ, Hannan KM, Poortinga G, Sheppard KE, Khanna KK, Johnstone RW, Drygin D, McArthur GA, Pearson RB, Sanij E, Hannan RD.

Oncotarget. 2016 Aug 2;7(31):49800-49818. doi: 10.18632/oncotarget.10452.

27.

Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia.

Ghisi M, Kats L, Masson F, Li J, Kratina T, Vidacs E, Gilan O, Doyle MA, Newbold A, Bolden JE, Fairfax KA, de Graaf CA, Firth M, Zuber J, Dickins RA, Corcoran LM, Dawson MA, Belz GT, Johnstone RW.

Cancer Cell. 2016 Jul 11;30(1):59-74. doi: 10.1016/j.ccell.2016.05.019. Epub 2016 Jun 30.

28.

CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity.

Boyle SE, Fedele CG, Corbin V, Wybacz E, Szeto P, Lewin J, Young RJ, Wong A, Fuller R, Spillane J, Speakman D, Donahoe S, Pohl M, Gyorki D, Henderson MA, Johnstone RW, Papenfuss AT, Shackleton M.

Cancer Res. 2016 Jul 1;76(13):3965-77. doi: 10.1158/0008-5472.CAN-15-2377. Epub 2016 Jun 20.

29.

Functional interdependence of BRD4 and DOT1L in MLL leukemia.

Gilan O, Lam EY, Becher I, Lugo D, Cannizzaro E, Joberty G, Ward A, Wiese M, Fong CY, Ftouni S, Tyler D, Stanley K, MacPherson L, Weng CF, Chan YC, Ghisi M, Smil D, Carpenter C, Brown P, Garton N, Blewitt ME, Bannister AJ, Kouzarides T, Huntly BJ, Johnstone RW, Drewes G, Dawson SJ, Arrowsmith CH, Grandi P, Prinjha RK, Dawson MA.

Nat Struct Mol Biol. 2016 Jul;23(7):673-81. doi: 10.1038/nsmb.3249. Epub 2016 Jun 13.

PMID:
27294782
30.

Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma.

Blombery P, Thompson ER, Jones K, Arnau GM, Lade S, Markham JF, Li J, Deva A, Johnstone RW, Khot A, Prince HM, Westerman D.

Haematologica. 2016 Sep;101(9):e387-90. doi: 10.3324/haematol.2016.146118. Epub 2016 May 19. No abstract available.

31.

The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.

Brumatti G, Ma C, Lalaoui N, Nguyen NY, Navarro M, Tanzer MC, Richmond J, Ghisi M, Salmon JM, Silke N, Pomilio G, Glaser SP, de Valle E, Gugasyan R, Gurthridge MA, Condon SM, Johnstone RW, Lock R, Salvesen G, Wei A, Vaux DL, Ekert PG, Silke J.

Sci Transl Med. 2016 May 18;8(339):339ra69. doi: 10.1126/scitranslmed.aad3099. Erratum in: Sci Transl Med. 2017 May 31;9(392):.

PMID:
27194727
32.

A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.

Yong CS, John LB, Devaud C, Prince MH, Johnstone RW, Trapani JA, Darcy PK, Kershaw MH.

Oncotarget. 2016 Jun 7;7(23):34582-98. doi: 10.18632/oncotarget.9149.

33.

How do tumor cells respond to HDAC inhibition?

Newbold A, Falkenberg KJ, Prince HM, Johnstone RW.

FEBS J. 2016 Nov;283(22):4032-4046. doi: 10.1111/febs.13746. Epub 2016 May 10. Review.

34.

The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock.

West AC, Martin BP, Andrews DA, Hogg SJ, Banerjee A, Grigoriadis G, Johnstone RW, Shortt J.

Oncogenesis. 2016 Apr 4;5:e216. doi: 10.1038/oncsis.2016.26.

35.

Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.

Waldeck K, Cullinane C, Ardley K, Shortt J, Martin B, Tothill RW, Li J, Johnstone RW, McArthur GA, Hicks RJ, Wood PJ.

Int J Cancer. 2016 Jul 1;139(1):194-204. doi: 10.1002/ijc.30056. Epub 2016 Mar 10.

36.

Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.

Valente LJ, Aubrey BJ, Herold MJ, Kelly GL, Happo L, Scott CL, Newbold A, Johnstone RW, Huang DC, Vassilev LT, Strasser A.

Cell Rep. 2016 Mar 1;14(8):1858-66. doi: 10.1016/j.celrep.2016.01.059. Epub 2016 Feb 18.

37.

A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity.

Falkenberg KJ, Newbold A, Gould CM, Luu J, Trapani JA, Matthews GM, Simpson KJ, Johnstone RW.

Cell Death Differ. 2016 Jul;23(7):1209-18. doi: 10.1038/cdd.2015.175. Epub 2016 Feb 12.

38.

Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.

Lalaoui N, Hänggi K, Brumatti G, Chau D, Nguyen NY, Vasilikos L, Spilgies LM, Heckmann DA, Ma C, Ghisi M, Salmon JM, Matthews GM, de Valle E, Moujalled DM, Menon MB, Spall SK, Glaser SP, Richmond J, Lock RB, Condon SM, Gugasyan R, Gaestel M, Guthridge M, Johnstone RW, Munoz L, Wei A, Ekert PG, Vaux DL, Wong WW, Silke J.

Cancer Cell. 2016 Feb 8;29(2):145-58. doi: 10.1016/j.ccell.2016.01.006. Erratum in: Cancer Cell. 2016 Sep 12;30(3):499-500.

39.

Serglycin determines secretory granule repertoire and regulates natural killer cell and cytotoxic T lymphocyte cytotoxicity.

Sutton VR, Brennan AJ, Ellis S, Danne J, Thia K, Jenkins MR, Voskoboinik I, Pejler G, Johnstone RW, Andrews DM, Trapani JA.

FEBS J. 2016 Mar;283(5):947-61. doi: 10.1111/febs.13649. Epub 2016 Jan 22.

40.

UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.

Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, Colebatch AJ, De Paoli-Iseppi R, Li J, Lupat R, Semple T, Arnau GM, Fellowes A, Leonard JH, Hruby G, Mann GJ, Thompson JF, Cullinane C, Johnston M, Shackleton M, Sandhu S, Bowtell DD, Johnstone RW, Fox SB, McArthur GA, Papenfuss AT, Scolyer RA, Gill AJ, Hicks RJ, Tothill RW.

Cancer Res. 2015 Dec 15;75(24):5228-34. doi: 10.1158/0008-5472.CAN-15-1877. Epub 2015 Dec 1.

41.

The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.

Baker A, Gregory GP, Verbrugge I, Kats L, Hilton JJ, Vidacs E, Lee EM, Lock RB, Zuber J, Shortt J, Johnstone RW.

Cancer Res. 2016 Mar 1;76(5):1158-69. doi: 10.1158/0008-5472.CAN-15-1070. Epub 2015 Dec 1.

42.

Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.

Devlin JR, Hannan KM, Hein N, Cullinane C, Kusnadi E, Ng PY, George AJ, Shortt J, Bywater MJ, Poortinga G, Sanij E, Kang J, Drygin D, O'Brien S, Johnstone RW, McArthur GA, Hannan RD, Pearson RB.

Cancer Discov. 2016 Jan;6(1):59-70. doi: 10.1158/2159-8290.CD-14-0673. Epub 2015 Oct 21.

43.

Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.

Matthews GM, Mehdipour P, Cluse LA, Falkenberg KJ, Wang E, Roth M, Santoro F, Vidacs E, Stanley K, House CM, Rusche JR, Vakoc CR, Zuber J, Minucci S, Johnstone RW.

Blood. 2015 Nov 19;126(21):2392-403. doi: 10.1182/blood-2015-03-632984. Epub 2015 Oct 7.

44.

BET inhibitor resistance emerges from leukaemia stem cells.

Fong CY, Gilan O, Lam EY, Rubin AF, Ftouni S, Tyler D, Stanley K, Sinha D, Yeh P, Morison J, Giotopoulos G, Lugo D, Jeffrey P, Lee SC, Carpenter C, Gregory R, Ramsay RG, Lane SW, Abdel-Wahab O, Kouzarides T, Johnstone RW, Dawson SJ, Huntly BJ, Prinjha RK, Papenfuss AT, Dawson MA.

Nature. 2015 Sep 24;525(7570):538-42. doi: 10.1038/nature14888. Epub 2015 Sep 14.

45.

Scribble acts as an oncogene in Eμ-myc-driven lymphoma.

Hawkins ED, Oliaro J, Ramsbottom KM, Newbold A, Humbert PO, Johnstone RW, Russell SM.

Oncogene. 2016 Mar 3;35(9):1193-7. doi: 10.1038/onc.2015.167. Epub 2015 May 18.

PMID:
25982280
46.

Manipulation of B-cell responses with histone deacetylase inhibitors.

Waibel M, Christiansen AJ, Hibbs ML, Shortt J, Jones SA, Simpson I, Light A, O'Donnell K, Morand EF, Tarlinton DM, Johnstone RW, Hawkins ED.

Nat Commun. 2015 Apr 27;6:6838. doi: 10.1038/ncomms7838.

PMID:
25913720
47.

Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia.

Salmon JM, Bots M, Vidacs E, Stanley KL, Atadja P, Zuber J, Johnstone RW.

Clin Epigenetics. 2015 Jan 22;7:2. doi: 10.1186/s13148-014-0034-4. eCollection 2015.

48.

CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.

Gregory GP, Hogg SJ, Kats LM, Vidacs E, Baker AJ, Gilan O, Lefebure M, Martin BP, Dawson MA, Johnstone RW, Shortt J.

Leukemia. 2015 Jun;29(6):1437-41. doi: 10.1038/leu.2015.10. Epub 2014 Jan 12. No abstract available.

49.

Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.

Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sékaly RP, Lewin SR.

PLoS Pathog. 2014 Nov 13;10(10):e1004473. doi: 10.1371/journal.ppat.1004473. eCollection 2014 Oct.

50.

Letter to the Editor, "BET inhibitor JQ1 blocks inflammation and bone destruction".

Hogg SJ, Johnstone RW, Shortt J.

J Dent Res. 2015 Jan;94(1):229. doi: 10.1177/0022034514557673. Epub 2014 Nov 11. No abstract available.

PMID:
25389001

Supplemental Content

Loading ...
Support Center